Previous Close | 1.2200 |
Open | 1.2500 |
Bid | 0.0000 x 1000 |
Ask | 0.0000 x 1000 |
Day's Range | 1.1700 - 1.2900 |
52 Week Range | 1.0300 - 43.5700 |
Volume | |
Avg. Volume | 170,901 |
Market Cap | 18.009M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.3570 |
Earnings Date | May 16, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for FBRX
DALLAS, May 16, 2022--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced first quarter 2022 results and provided a business update.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Forte Biosciences, Inc. (“Forte” or the “Company”) (NASDAQ: FBRX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Forte and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class acti